Overview

Molecularly Tailored Therapy for Pancreas Cancer

Status:
Completed
Trial end date:
2018-01-24
Target enrollment:
Participant gender:
Summary
Patient therapy is tailored according to the molecular profile of the patient's tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Georgetown University
Treatments:
Camptothecin
Docetaxel
Fluorouracil
Gemcitabine
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin